Panacea Life Sciences Holdings, Inc. (PLSH) stock
PLSHOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q1 FY2024, quarter ended Mar 31, 2024Last filing: 10-Q on May 6, 2024
$0.07+0.00 (+5.45%)
Close on Oct 19, 2026Market cap $1.15MP/E –Yield –
Panacea Life Sciences gross margin
Gross margin is gross profit as a percentage of revenue.
Panacea Life Sciences's gross margin for the twelve months ending Mar 31, 2024 was 56.5%. For fiscal 2023 it was 47.0%, against 24.4% the year before. The highest annual figure on record is 47.0% in fiscal 2023.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 47.0% | +22.7 |
| FY2022 | Dec 31, 2022 | 24.4% | −1.9 |
| FY2021 | Dec 31, 2021 | 26.2% | +4.1 |
| FY2020 | Dec 31, 2020 | 22.2% | +514.1 |
| FY2019 | Dec 31, 2019 | -491.9% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2024 | Mar 31, 2024 | 63.1% | +29.8 |
| Q4 FY2023 | Dec 31, 2023 | 56.9% | +22.8 |
| Q3 FY2023 | Sep 30, 2023 | 42.1% | +29.2 |
| Q2 FY2023 | Jun 30, 2023 | 50.8% | +21.4 |
| Q1 FY2023 | Mar 31, 2023 | 33.3% | +11.8 |
| Q4 FY2022 | Dec 31, 2022 | 34.1% | +32.5 |
| Q3 FY2022 | Sep 30, 2022 | 12.9% | −35.2 |
| Q2 FY2022 | Jun 30, 2022 | 29.4% | +8.7 |
| Q1 FY2022 | Mar 31, 2022 | 21.5% | −14.1 |
| Q4 FY2021 | Dec 31, 2021 | 1.6% | +4.7 |
| Q3 FY2021 | Sep 30, 2021 | 48.1% | +164.4 |
| Q2 FY2021 | Jun 30, 2021 | 20.7% | −31.0 |
| Q1 FY2021 | Mar 31, 2021 | 35.6% | +103.1 |
| Q4 FY2020 | Dec 31, 2020 | -3.1% | +1306.0 |
| Q3 FY2020 | Sep 30, 2020 | -116.3% | −49.3 |
| Q2 FY2020 | Jun 30, 2020 | 51.7% | +118.6 |
| Q1 FY2020 | Mar 31, 2020 | -67.5% | −88.6 |
| Q4 FY2019 | Dec 31, 2019 | -1309.1% | – |
| Q3 FY2019 | Sep 30, 2019 | -66.9% | – |
| Q2 FY2019 | Jun 30, 2019 | -66.9% | – |
| Q1 FY2019 | Mar 31, 2019 | 21.2% | – |
See a number that looks wrong?